The majority of biomedical innovation is developed by emerging biopharma (EBP) companies, many of which have never marketed a therapy before. Over time, those companies either successfully bring their products to market or, in many cases, their assets or whole companies are acquired by others. These EBP companies are at the root of early-stage drug development and their performance, the environment in which they operate, and their relationship to other stakeholders in the health system play a critical role in determining the future of many novel therapies and health technologies.
This report is intended to inform executives from these emerging biopharma companies (EBPs), their investors, the large pharma company executives who engage with EBPs and often purchase their assets, as well as policymakers focused on the overall innovation ecosystem. It also has a global focus – as innovation knows no borders – and includes novel analytics across a range of relevant topics.
The report provides clarity on the current landscape of EBP companies and their emerging product pipelines, as well as associated clinical trial activity and levels of trial success. In addition, the report focuses on the financial deals, technology, and approaches to enable and accelerate these companies’ efforts, profiling the drugs these companies have launched or originated, and an assessment of the success of launches in recent years, including nuances beyond simply sales uptake.
Read More: https://www.iqvia.com/Insights/The-IQVIA-Institute/Reports/Emerging-Biopharma-Contribution-to-Innovation?utm_campaign=2022_EmergingBio_GBU_RDS_TC&utm_medium=email&utm_source=Eloqua